SG11201408521WA - Use of ferric citrate in the treatment of chronic kidney disease patients - Google Patents
Use of ferric citrate in the treatment of chronic kidney disease patientsInfo
- Publication number
- SG11201408521WA SG11201408521WA SG11201408521WA SG11201408521WA SG11201408521WA SG 11201408521W A SG11201408521W A SG 11201408521WA SG 11201408521W A SG11201408521W A SG 11201408521WA SG 11201408521W A SG11201408521W A SG 11201408521WA SG 11201408521W A SG11201408521W A SG 11201408521WA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- rule
- iron
- kidney disease
- chronic kidney
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/295—Iron group metal compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/26—Iron; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Inorganic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261662565P | 2012-06-21 | 2012-06-21 | |
| US201361757229P | 2013-01-28 | 2013-01-28 | |
| US201361801050P | 2013-03-15 | 2013-03-15 | |
| US201361800618P | 2013-03-15 | 2013-03-15 | |
| PCT/US2013/047134 WO2013192565A2 (en) | 2012-06-21 | 2013-06-21 | Use of ferric citrate in the treatment of chronic kidney disease patients |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201408521WA true SG11201408521WA (en) | 2015-01-29 |
Family
ID=49769729
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201408521WA SG11201408521WA (en) | 2012-06-21 | 2013-06-21 | Use of ferric citrate in the treatment of chronic kidney disease patients |
| SG10201805177PA SG10201805177PA (en) | 2012-06-21 | 2013-06-21 | Use of ferric citrate in the treatment of chronic kidney disease patients |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201805177PA SG10201805177PA (en) | 2012-06-21 | 2013-06-21 | Use of ferric citrate in the treatment of chronic kidney disease patients |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US20130345303A1 (enExample) |
| EP (3) | EP4335436A3 (enExample) |
| JP (4) | JP2015535209A (enExample) |
| KR (2) | KR102150135B1 (enExample) |
| CN (2) | CN113244209A (enExample) |
| AU (2) | AU2013278000A1 (enExample) |
| BR (1) | BR112014032049A2 (enExample) |
| CA (1) | CA2876982A1 (enExample) |
| DK (1) | DK3730136T3 (enExample) |
| EA (1) | EA201590062A1 (enExample) |
| ES (2) | ES2970050T3 (enExample) |
| HK (1) | HK1214503A1 (enExample) |
| IL (1) | IL236356A0 (enExample) |
| MX (1) | MX2014015615A (enExample) |
| NO (1) | NO2025048I1 (enExample) |
| PL (1) | PL3730136T3 (enExample) |
| SG (2) | SG11201408521WA (enExample) |
| WO (1) | WO2013192565A2 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2010276242B2 (en) | 2009-07-21 | 2014-05-29 | Keryx Biopharmaceuticals, Inc. | Ferric citrate dosage forms |
| TWI653043B (zh) * | 2012-12-20 | 2019-03-11 | 瑞士商伊蘭科動物健康公司 | 新用途 |
| DK3287133T3 (da) | 2013-06-05 | 2019-07-01 | Tricida Inc | Proton-bindende polymerer til oral indgivelse |
| EP2856941B1 (en) * | 2013-10-01 | 2020-11-25 | Fresenius Medical Care Deutschland GmbH | Method and apparatuses for determining a patient's daily loss of iron |
| EP3747432A1 (en) * | 2013-11-04 | 2020-12-09 | Keryx Biopharmaceuticals, Inc. | Ferric citrate for reducing cardiac failure in chronic kidney disease patients |
| WO2015110968A1 (en) * | 2014-01-23 | 2015-07-30 | Lupin Limited | Pharmaceutical grade ferric citrate and method for its production |
| WO2015198304A1 (en) | 2014-06-22 | 2015-12-30 | Dexcel Pharma Technologies Ltd. | Pharmaceutical compositions comprising ferric citrate and methods for the production thereof |
| KR102625115B1 (ko) | 2014-12-10 | 2024-01-12 | 트리시다, 인크. | 경구 투여용 양성자-결합 폴리머 |
| BR112017018963A2 (pt) * | 2015-03-04 | 2018-05-15 | Keryx Biopharmaceuticals Inc | método para tratar anemia por deficiência de ferro |
| CN104688706B (zh) * | 2015-04-01 | 2017-07-14 | 成都欣捷高新技术开发有限公司 | 一种高载药量、快速溶出的枸橼酸铁组合物及其制备方法 |
| WO2016162794A1 (en) * | 2015-04-08 | 2016-10-13 | Leiutis Pharmaceuticals Pvt Ltd | Pharmaceutical compositions of ferric citrate |
| WO2016162888A1 (en) * | 2015-04-09 | 2016-10-13 | Actavis Group Ptc Ehf. | Process for preparing pharmaceutical grade ferric citrate |
| KR102655774B1 (ko) | 2016-05-06 | 2024-04-05 | 트리시다, 인크. | 산-염기 장애의 치료를 위한 조성물 및 방법 |
| JP7387435B2 (ja) | 2017-09-19 | 2023-11-28 | 日本たばこ産業株式会社 | 過多月経患者及び／又は過多月経を伴う婦人科疾患を有する患者における鉄欠乏性貧血の予防及び／又は治療におけるクエン酸第二鉄の使用 |
| IL319146A (en) | 2017-11-03 | 2025-04-01 | Tricida Inc | Compositions for and method of treating acid-base disorders |
| WO2019236639A1 (en) * | 2018-06-04 | 2019-12-12 | Tricida, Inc. | Method of treating acid-base disorders |
| CA3117071A1 (en) | 2018-10-29 | 2020-05-07 | Pharmacosmos Holding A/S | Treating iron deficiency with ferric carboxymaltose |
| WO2022150623A1 (en) | 2021-01-08 | 2022-07-14 | Akebia Therapeutics, Inc. | Compounds and composition for the treatment of anemia |
| TW202313072A (zh) | 2021-05-27 | 2023-04-01 | 美商凱立克斯生物製藥股份有限公司 | 檸檬酸鐵之兒科調配物 |
| CN115024495B (zh) * | 2022-06-27 | 2024-03-22 | 北京金康普食品科技有限公司 | 改善肾病患者钙磷代谢的营养组合物及其应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0922461A4 (en) * | 1996-07-19 | 2002-07-17 | Nikken Chemicals Co Ltd | MEDICINE AGAINST HYPERPHOSPHATANEMIA |
| US5753706A (en) * | 1996-12-16 | 1998-05-19 | Hsu; Chen Hsing | Methods for treating renal failure |
| US8093423B2 (en) | 2003-02-19 | 2012-01-10 | Globoasia, Llc | Pharmaceutical-grade ferric organic compounds, uses thereof and method of making same |
| TWI335218B (en) | 2003-02-19 | 2011-01-01 | Panion & Bf Biotech Inc | Ferric organic compounds, uses thereof and methods of making same |
| CN1600302A (zh) * | 2003-09-22 | 2005-03-30 | 宝龄富锦生技股份有限公司 | 含有柠檬酸铁的医药组合物以及药用级柠檬酸铁及其制法和含有药用级柠檬酸铁的膳食营养品 |
| US20060134227A1 (en) * | 2004-12-22 | 2006-06-22 | Bortz Jonathan D | Compositions including iron |
| MX2008002360A (es) | 2005-08-18 | 2008-04-29 | Globoasia Llc | Compuestos organicos ferricos grado farmaceutico, uso de los mismos y metodos para elaborar los mismos. |
| AU2007205167B2 (en) * | 2006-01-06 | 2013-06-13 | Vifor (International) Ag | Methods and compositions for administration of iron |
| CN101374416A (zh) | 2006-01-30 | 2009-02-25 | 环亚有限公司 | 逆转、防止、延迟或稳定软组织钙化的方法 |
| AU2010276242B2 (en) | 2009-07-21 | 2014-05-29 | Keryx Biopharmaceuticals, Inc. | Ferric citrate dosage forms |
-
2013
- 2013-06-21 US US13/924,332 patent/US20130345303A1/en not_active Abandoned
- 2013-06-21 SG SG11201408521WA patent/SG11201408521WA/en unknown
- 2013-06-21 CA CA2876982A patent/CA2876982A1/en not_active Abandoned
- 2013-06-21 PL PL20163104.1T patent/PL3730136T3/pl unknown
- 2013-06-21 EP EP23219273.2A patent/EP4335436A3/en not_active Withdrawn
- 2013-06-21 ES ES20163104T patent/ES2970050T3/es active Active
- 2013-06-21 AU AU2013278000A patent/AU2013278000A1/en not_active Abandoned
- 2013-06-21 WO PCT/US2013/047134 patent/WO2013192565A2/en not_active Ceased
- 2013-06-21 DK DK20163104.1T patent/DK3730136T3/da active
- 2013-06-21 JP JP2015518623A patent/JP2015535209A/ja active Pending
- 2013-06-21 HK HK16102352.0A patent/HK1214503A1/zh unknown
- 2013-06-21 SG SG10201805177PA patent/SG10201805177PA/en unknown
- 2013-06-21 ES ES13807102T patent/ES2796254T3/es active Active
- 2013-06-21 MX MX2014015615A patent/MX2014015615A/es unknown
- 2013-06-21 KR KR1020157001458A patent/KR102150135B1/ko active Active
- 2013-06-21 EP EP20163104.1A patent/EP3730136B1/en active Active
- 2013-06-21 EA EA201590062A patent/EA201590062A1/ru unknown
- 2013-06-21 KR KR1020207024260A patent/KR20200103855A/ko not_active Ceased
- 2013-06-21 CN CN202110644193.4A patent/CN113244209A/zh active Pending
- 2013-06-21 CN CN201380044271.0A patent/CN104884055A/zh active Pending
- 2013-06-21 BR BR112014032049A patent/BR112014032049A2/pt not_active IP Right Cessation
- 2013-06-21 EP EP13807102.2A patent/EP2863906B1/en active Active
-
2014
- 2014-04-25 US US14/262,465 patent/US20140234416A1/en not_active Abandoned
- 2014-10-24 US US14/523,656 patent/US20150079168A1/en not_active Abandoned
- 2014-12-18 IL IL236356A patent/IL236356A0/en unknown
-
2018
- 2018-04-10 JP JP2018075243A patent/JP2018138562A/ja active Pending
- 2018-05-08 AU AU2018203205A patent/AU2018203205B2/en not_active Ceased
-
2020
- 2020-02-25 JP JP2020029756A patent/JP2020100638A/ja active Pending
-
2022
- 2022-02-10 JP JP2022019167A patent/JP2022070945A/ja active Pending
-
2025
- 2025-11-06 NO NO2025048C patent/NO2025048I1/no unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201408521WA (en) | Use of ferric citrate in the treatment of chronic kidney disease patients | |
| SG11201908391XA (en) | Methods for modulating an immune response | |
| SG11201909955XA (en) | Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies | |
| SG11201408318RA (en) | Compositions and methods for transmucosal absorption | |
| SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
| SG11201811564QA (en) | Methods of treating ovarian cancer | |
| SG11201407859YA (en) | Methods of treating cancer using pd-l1 axis binding antagonists and vegf antagonists | |
| SG11201407851RA (en) | Synthesis of pyrrolo [2, 3 - b] pyridines | |
| SG11201407669QA (en) | Methods for improving safety of blood-brain barrier transport | |
| SG11201804161VA (en) | Compositions comprising bacterial strains | |
| SG11201408780XA (en) | Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof | |
| SG11201808990QA (en) | Compositions for topical application of compounds | |
| SG11201804373VA (en) | Compositions and methods for immunooncology | |
| SG11201805420SA (en) | Antibodies and conjugates thereof | |
| SG11201804729RA (en) | Methods and compositions for treating a serpinc1-associated disorder | |
| SG11201901961SA (en) | Methods of using a bispecific antibody that recognizes coagulation factor ix and/or activated coagulation factor ix and coagulation factor x and/or activated coagulation factor x | |
| SG11201407508RA (en) | Encoding and decoding based on blending of sequences of samples along time | |
| SG11201810628XA (en) | Nasal pharmaceutical compositions with a porous excipient | |
| SG11201808106YA (en) | Use of masitinib for treatment of an amyotrophic lateral sclerosis patient subpopulation | |
| SG11201403106SA (en) | Anti-phf-tau antibodies and their uses | |
| SG11201804704PA (en) | Compositions and methods for decreasing tau expression | |
| SG11201803676PA (en) | Site specific her2 antibody drug conjugates | |
| SG11201807677YA (en) | Antibodies to cd40 with enhanced agonist activity | |
| SG11201408240TA (en) | Treatment of motor and movement disorder side effects associated with parkinson's disease treatments | |
| SG11201804770QA (en) | Method and arrangement for recovery of salt |